+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cholera Vaccines Market Size, Share & Trends Analysis Report By Product (Dukoral, Shanchol, Vaxchora), By Region (North America, APAC, Europe, MEA, Latin America), And Segment Forecasts, 2018 - 2025

  • PDF Icon

    Report

  • 87 Pages
  • August 2018
  • Region: Global
  • Grand View Research
  • ID: 4621706
The global cholera vaccines market size is expected to reach USD 117.1 million by 2025, exhibiting a CAGR of 8.2% during the forecast period. Increase in number of initiatives and rising awareness about cholera are major factors contributing toward market growth.

Governments in regions affected by cholera are striving to eliminate the disease by developing a strong public health and sanitation infrastructure. In February 2013, the Government of Haiti launched a 10-year National Cholera Elimination Plan. The United Nations Organization has made elimination of cholera a key UN priority and offers support to the Haitian Government by establishing a mechanism to respond to an alert within 48 hours, household visits, and sensitization campaigns.

Furthermore, various research projects and studies, such as epidemiological and anthropological studies, are being conducted in Africa. Ongoing studies include using rapid diagnostics tests to detect Vibrio cholerae in samples of water to understand epidemic diffusion mechanisms and anticipate outbreaks. The Cholera Platform is working with the Global Task Force for Cholera Control (GTFCC) WASH working group. This association aims to develop a method for conducting case studies to control and prevent the disease.

Further key findings from the report suggest:
  • The global market size was estimated at USD 63.1 million in 2017 and is expected to register a CAGR of 8.2% from 2017 to 2025

  • By product, Dukoral vaccine dominated the market in 2017. The dominance can be attributed to the positive outcomes of this vaccine in preventing the disease since 2004. Dukoral is considered to be safe and stable

  • The Vaxchora segment is expected to exhibit a lucrative CAGR over the forecast period owing to benefits associated with the vaccine, such as single dose immunization and reduced adverse effects

  • Asia Pacific held the largest share in 2017 due to factors such as increasing incidence and growing initiatives for raising awareness about the disease and vaccination

  • North America is anticipated to witness lucrative growth over the next decade due to a recent product launch and increasing number of travelers

  • Some of the key players are Valneva SE; Shantha Biotechnics Private Limited; and PaxVax, Inc.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1 Executive Summary
1.1 Market Snapshot
Chapter 2 Methodology and Scope
2.1 Information Procurement
2.1.1 Purchased database:
2.1.2 Internal database
2.2 Research Methodology
2.3 Geographic Scope & Assumptions
2.4 Region-wise Market Calculation
2.4.1 Region-wise market: Base estimates
2.4.2 Global market: CAGR calculation
2.5 Region-based segment share calculation
2.6 List of Secondary Sources
Chapter 3 Cholera Vaccines Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.2 Market size and growth prospects
3.2.1 Market Driver Analysis
3.2.1.1 Rise in importance of immunization across the globe
3.2.1.2 High incidence of cholera
3.2.1.3 Rise in number of initiatives to control cholera
3.2.2 Market restraint analysis
3.2.2.1 Adverse effects of vaccines
3.3 Penetration & Growth Prospect Mapping
3.4 Cholera Vaccines - SWOT Analysis, By Factor (political & legal, economic and technological)
3.5 Industry Analysis - Porter’s
Chapter 4 Cholera Vaccines Market: Product Estimates & Trend Analysis
4.1 Cholera Vaccines Market: Product Movement Analysis
4.2 Dukoral
4.2.1 Dukoral market, 2013 - 2025 (USD Million)
4.3 Shanchol
4.3.1 Shanchol market, 2013 - 2025 (USD Million)
4.4 Vaxchora
4.4.1 Vaxchora market, 2013 - 2025 (USD Million)
4.5 Others
4.5.1 Other cholera vaccines market, 2013 - 2025 (USD Million)
Chapter 5 Cholera Vaccines Market: Regional Estimates & Trend Analysis
5.1 Cholera vaccines market share by region, 2017 & 2025
5.2 North America
5.2.1 North America cholera vaccines market, 2013 - 2025 (USD Million)
5.2.2 U.S.
5.2.2.1 U.S. cholera vaccines market, 2013 - 2025 (USD Million)
5.2.3 Canada
5.2.3.1 Canada cholera vaccines market, 2013 - 2025 (USD Million)
5.3 Europe
5.3.1 Europe cholera vaccines market, 2013 - 2025 (USD Million)
5.3.2 Germany
5.3.2.1 Germany cholera vaccines market, 2013 - 2025 (USD Million)
5.3.3 U.K.
5.3.3.1 U.K. cholera vaccines market, 2013 - 2025 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific cholera vaccines market, 2013 - 2025 (USD Million)
5.4.2 China
5.4.2.1 China cholera vaccines market, 2013 - 2025 (USD Million)
5.4.3 India
5.4.3.1 India cholera vaccines market, 2013 - 2025 (USD Million)
5.5 Latin America
5.5.1 Latin America cholera vaccines market, 2013 - 2025 (USD Million)
5.5.2 Brazil
5.5.2.1 Brazil cholera vaccines market, 2013 - 2025 (USD Million)
5.6 Middle East & Africa (MEA)
5.6.1 MEA cholera vaccines market, 2013 - 2025 (USD Million)
5.6.2 South Africa
5.6.2.1 South Africa cholera vaccines market, 2013 - 2025 (USD Million)
Chapter 6 Competitive Landscape
6.1 Strategy Framework
6.2 Company Profiles
6.2.1 Shantha Biotechnics Private Limited
6.2.1.1 Company overview
6.2.1.2 Financial performance
6.2.1.3 Product benchmarking
6.2.1.4 Strategic initiatives
6.2.2 Valneva SE
6.2.2.1 Company overview
6.2.2.2 Financial performance
6.2.2.3 Product benchmarking
6.2.2.4 Strategic initiatives
6.2.3 PaxVax, Inc.
6.2.3.1 Company overview
6.2.3.2 Financial performance
6.2.3.3 Product benchmarking
6.2.3.4 Strategic initiatives
6.2.4 Astellas Pharma, Inc.
6.2.4.1 Company overview
6.2.4.2 Product benchmarking
6.2.4.3 Strategic initiatives
6.2.5 Merck & Co., Inc.
6.2.5.1 Company overview
6.2.5.2 Financial performance
6.2.5.3 Product benchmarking
6.2.5.4 Strategic initiatives
6.2.6 GlaxoSmithKline plc (GSK)
6.2.6.1 Company overview
6.2.6.2 Financial performance
6.2.6.3 Product benchmarking
6.2.6.4 Strategic initiatives
6.2.7 Pfizer, Inc.
6.2.7.1 Company overview
6.2.7.2 Financial performance
6.2.7.3 Product benchmarking
6.2.7.4 Strategic initiatives
6.2.8 Takeda Pharmaceutical Co., Ltd.
6.2.8.1 Company overview
6.2.8.2 Financial performance
6.2.8.3 Product benchmarking
6.2.8.4 Strategic initiatives
6.2.9 Emergent BioSolutions, Inc.
6.2.9.1 Company overview
6.2.9.2 Product benchmarking
6.2.9.3 Strategic initiatives
6.2.10 AstraZeneca
6.2.10.1 Company overview
6.2.10.2 Financial performance
6.2.10.3 Product benchmarking
6.2.10.4 Strategic initiatives
6.2.11 Mitsubishi Tanabe Pharma Corporation
6.2.11.1 Company overview
6.2.11.2 Financial performance
6.2.11.3 Product benchmarking
6.2.11.4 Strategic initiatives
List of Tables
Table 1 Country share estimation
Table 2 North America cholera vaccines market, by product, 2013 - 2025 (USD Million)
Table 3 U.S. cholera vaccines market, by product, 2013 - 2025 (USD Million)
Table 4 Canada cholera vaccines market, by product, 2013 - 2025 (USD Million)
Table 5 Europe cholera vaccines market, by product, 2013 - 2025 (USD Million)
Table 6 Germany cholera vaccines market, by product, 2013 - 2025 (USD Million)
Table 7 U.K. cholera vaccines market, by product, 2013 - 2025 (USD Million)
Table 8 Asia Pacific cholera vaccines market, by product, 2013 - 2025 (USD Million)
Table 9 China cholera vaccines market, by product, 2013 - 2025 (USD Million)
Table 10 India cholera vaccines market, by product, 2013 - 2025 (USD Million)
Table 11 Latin America cholera vaccines market, by product, 2013 - 2025 (USD Million)
Table 12 Brazil cholera vaccines market, by product, 2013 - 2025 (USD Million)
Table 13 MEA cholera vaccines market, by product, 2013 - 2025 (USD Million)
Table 14 South Africa cholera vaccines market, by product, 2013 - 2025 (USD Million)
List of Figures
FIG. 1 Market summary
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Value chain-based sizing & forecasting
FIG. 5 QFD modelling for market share assessment
FIG. 6 Market trends & outlook
FIG. 7 Market segmentation & scope
FIG. 8 Global cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 9 Market driver relevance analysis (Current & future impact)
FIG. 10 Administration of Dukoral or Shanchol in post-licensure oral cholera vaccination campaigns globally, 1997 - 2014
FIG. 11 Reported cases of cholera by continent and by year (2011-2016)
FIG. 12 Market restrain relevance analysis (Current & future impact)
FIG. 13 Penetration & growth prospect mapping
FIG. 14 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 15 Porter’s Five Forces Analysis
FIG. 16 Cholera vaccines market product outlook key takeaways
FIG. 17 Cholera vaccines market: Product movement analysis
FIG. 18 Global Dukoral market, 2013 - 2025 (USD Million)
FIG. 19 Global Shanchol market, 2013 - 2025 (USD Million)
FIG. 20 Global Vaxchora market, 2013 - 2025 (USD Million)
FIG. 21 Global other cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 22 Regional market place: Key takeaways
FIG. 23 Cholera vaccines market: Regional movement analysis
FIG. 24 North America cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 25 U.S. cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 26 Canada cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 27 Europe cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 28 Germany cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 29 U.K. cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 30 Asia Pacific cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 31 China cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 32 India cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 33 Latin America cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 34 Brazil cholera vaccines market, 2015 - 2025 (USD Million)
FIG. 35 MEA cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 36 South Africa cholera vaccines market, 2013 - 2025 (USD Million)
FIG. 37 Strategy framework

Companies Mentioned

  • Shantha Biotechnics Private Limited

  • Valneva SE

  • PaxVax, Inc.

  • Astellas Pharma, Inc.

  • Merck & Co., Inc.

  • GlaxoSmithKline plc (GSK)

  • Pfizer, Inc.

  • Takeda Pharmaceutical Co., Ltd.

  • Emergent BioSolutions, Inc.

  • AstraZeneca

  • Mitsubishi Tanabe Pharma Corporation

Methodology

Loading
LOADING...